It was reported here in March 2017 that BioTime, Inc. is conducting a Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. OpRegen is a retinal pigment epithelium (RPE) stem cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). RPE cells are essential […]
by Dan Roberts June 2013 INTRODUCTION This is a summary of reports about significant research and development in the field of macular degeneration and related diseases presented since June 2012 and May 2013. I will briefly describe the conclusions of 77 studies that have been presented in the areas of therapy, prevention, technology, nutrition and […]
by Dan Roberts (Updated February 20, 2015) Several studies are showing success at using stem cell transplantation to treat retinal degeneration. This article describes the progress of the research. University of Washington In 2006, a team from the University of Washington used a mix of “growth factors”, natural proteins that encourage cell growth, to coax […]
by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single […]
Compiled and edited by Dan Roberts JUNE 2007 Omega-3 Proving to be Beneficial on Several Fronts Recent studies have shown that Omega-3 fatty acids and fish consumption may reduce the risks of age-related macular degeneration (AMD), Alzheimer’s disease, inflammation and depression. The Age-Related Eye Disease Study (AREDS) Research Group showed that dietary total Omega-3 and […]